 STANS, SWITZERLAND ACCESSWIRE October 14, 2021 NLS Pharmaceutics Ltd. NASDAQ:NLSP, NLSPW NLS or the Company, a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces preclinical data for NLS-4 Lauflumide, the Companys next-generation wake-promoting drug candidate, which has shown promise for the treatment of chronic fatigue associated with Long-COVID also known as chronic COVID syndrome. 